Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Diabetes Technology & Therapeutics|August 5, 2015
The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise StudyIgnacio Conget, Javier Castaneda, Goran Petrovski, et al.
Diabetes, Obesity & Metabolism|August 4, 2025
Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trialsRonnie Aronson, Alexander Abitbol, Harpreet S Bajaj, et al.
Diabetes, Obesity & Metabolism|April 5, 2017
Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trialMuriel Metzger, Javier Castañeda, Yves Reznik, et al.
The Journal of Clinical Endocrinology and Metabolism|May 14, 2020
Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and DapagliflozinNatalia McInnes, Stephanie Hall, Farah Sultan, et al.
Diabetes, Obesity & Metabolism|November 21, 2018
Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studiesUlrik Pedersen-Bjergaard, Saud Alsifri, Ronnie Aronson, et al.
Diabetes Care|May 26, 2016
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 TrialJulio Rosenstock, Bruno Guerci, Markolf Hanefeld, et al.
Canadian Journal of Diabetes|June 25, 2022
Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA TrialHarpreet S Bajaj, Lisa Chu, Nandini Bansal, et al.
Diabetes, Obesity & Metabolism|January 24, 2023
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetesSimon Heller, Tadej Battelino, Timothy S Bailey, et al.
Diabetes Care|March 5, 2010
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugsSanne G Swinnen, Marie-Paule Dain, Ronnie Aronson, et al.
Annals of Internal Medicine|August 23, 2017
Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized TrialRoy W Beck, Tonya D Riddlesworth, Katrina Ruedy, et al.
Pageof 7